  PULSAR (personalized, ultra-fractionated stereotactic adaptive radiotherapy)
is the adaptation of stereotactic ablative radiotherapy towards personalized
cancer management. For the first time, we applied a transformer-based attention
mechanism to investigate the underlying interactions between combined PULSAR
and PD-L1 blockade immunotherapy based on a murine cancer model (Lewis Lung
Carcinoma, LLC). The proposed approach is able to predict the trend of tumor
volume change semi-quantitatively, and excels in identifying the potential
causal relationships through both self-attention and cross-attention scores.
